^Eindhoven, Sept 05, 2023 (GLOBE NEWSWIRE) — ONWARD Medical NV (Euronext:
ONWD), the medical technology company bringing innovative therapies to
Restoring movement, function, and independence in people with
Spinal Cord Injury developed announced today that there will be a webcast
to present its business highlights for the half-year 2023
discuss.
The webcast will take place on September 19, 2023 at 2pm CET / 8am ET.
It will be moderated by CEO Dave Marver and CFO Lara Smith Weber
Discuss highlights of the 2023 half-year and give a business update.
To participate in the webcast via Zoom, please register via this
Link (https://onwd.zoom.us/webinar/register/WN_q8A4aB4_TiKAUn3tJ6t84g).
Participants can also be connected by telephone:
+32 2 290 9360 (Belgium)
+49 69 3807 9884 (Germany)
+31 20 794 0854 (Netherlands)
+41 22 591 0156 (Switzerland)
+44 203 481 5240 (UK)
+1 346 248 7799 (US)
Other phone numbers available
(https://us02web.zoom.us/zoomconference?m=ODQwMDc2ODQ3NDU.4Z9dvTMoCvaEym4uZVHhEo
kjpEutPTPB&_x_zm_rtaid=bZlEbl_NSXC-
Td9ETD5uUg.1666686155946.2fb4a8093478ce9dedddbf91807a4829&_x_zm_rhtaid=97)
Webinar ID: 884 9100 3320
A replay of the webcast will follow the live event
(https://ir.onwd.com/financial-information) on the company’s website
be available.
About ONWARD Medical
ONWARD is a medical technology company that provides therapies for recovery
of movement, function and independence in people with
developed spinal cord injuries and restricted mobility. Based on
more than a decade of scientific and preclinical research conducted in
the company has conducted in leading neuroscience laboratories
nine breakthrough device designations from the US Food and Drug Administration
for its ARC Therapy Platform(TM).
ONWARD® ARC Therapy, performed with external ARC-EX(TM) or implantable ARC-IM
Systems(TM) is designed to provide a targeted,
enable programmed spinal cord stimulation. In 2023 became positive
Results of the company’s pivotal study called Up-LIFT
presented in the ability to improve transcutaneous ARC therapy
the strength and function of the upper extremities was assessed. The company
is preparing to submit regulatory submissions for ARC-EX in the US
and Europe before. In parallel, the company conducts studies with its
implantable ARC-IM platform through 2022 positive preliminary
clinical results for improved blood pressure regulation after a
showed spinal cord injury. Other ongoing studies deal with the
combined use of ARC-IM with a brain-computer interface
(BCI).
ONWARD is headquartered in Eindhoven, The Netherlands and has a
Science and Development Center in Lausanne, Switzerland and a US office in
Boston, Mass. The company also maintains an academic
partnership with. NeuroRestore, a collaboration between the
Swiss Federal Institute of Technology (EPFL) and the University Hospital
Lausanne (CHUV).
For more information visit ONWD.com and
(http://www.onwd.com/)connect with us on LinkedIn
(https://www.linkedin.com/company/onwdempowered/) and YouTube
(https://www.youtube.com/@ONWARD_EMPOWERED/videos).
waiver
Certain statements, beliefs and opinions contained in this press release are
forward-looking and reflect the current expectations and forecasts of the
company or the directors of the company with respect to future
events reflected. By their nature, forward-looking statements include several
Risks, uncertainties and assumptions that may cause the
actual results or events differ materially from those set forth in the
results expressed or implied by any forward-looking statement; or
events differ. These risks, uncertainties and assumptions may change
detrimental to earnings and the financial impact of here
plans and events described. A variety of factors
including but not limited to changes in demand,
Competition and technology can cause the actual
Events, performance or results differ significantly from anticipated developments
differ. The forward-looking statements contained in this press release
Statements regarding past trends or activities should not be taken as a representation
be understood that such trends or activities will occur in the future
will continue. As a result, the company expressly disclaims any
Obligation or obligation from, updates or revisions of
to release any forward-looking statements in this press release that
arise from a change in expectations or a change in events,
Conditions, assumptions or circumstances upon which these forward-looking statements are based
statements are based. Neither the Company nor its advisers or agents, nor
any of its subsidiaries or its officers or employees
such a person guarantee that the assumptions made by such
underlying forward-looking statements are free of errors, and none
of them accepts responsibility for the future correctness of the in
forward-looking statements contained in this press release or the
actual occurrence of the forecast developments. You should yourself
not place undue reliance on forward-looking statements, which are made only as of the date
of the publication of this press release. All ONWARD products and
-therapies referred to herein, including but not limited to
limited to ARC-IM, ARC-EX and ARC-Therapy, are under investigation and
are not available for commercial use.
°